000141812 001__ 141812
000141812 005__ 20240229112527.0
000141812 0247_ $$2doi$$a10.1158/1055-9965.EPI-18-0378
000141812 0247_ $$2pmid$$apmid:30487132
000141812 0247_ $$2ISSN$$a1055-9965
000141812 0247_ $$2ISSN$$a1538-7755
000141812 0247_ $$2altmetric$$aaltmetric:56427958
000141812 037__ $$aDKFZ-2018-02080
000141812 041__ $$aeng
000141812 082__ $$a610
000141812 1001_ $$0P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aGuan, Zhong$$b0$$eFirst author$$udkfz
000141812 245__ $$aWhole-blood DNA methylation markers in early detection of breast cancer: a systematic literature review.
000141812 260__ $$aPhiladelphia, Pa.$$bAACR$$c2019
000141812 3367_ $$2DRIVER$$aarticle
000141812 3367_ $$2DataCite$$aOutput Types/Journal article
000141812 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1562071433_20048$$xReview Article
000141812 3367_ $$2BibTeX$$aARTICLE
000141812 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141812 3367_ $$00$$2EndNote$$aJournal Article
000141812 520__ $$aWhole-blood DNA methylation markers have been suggested as potential biomarkers for early detection of breast cancer (BC). We conducted a systematic review of literature on whole-blood DNA methylation markers for BC detection. PubMed and ISI Web of Knowledge were searched up to 29th May 2018. Overall, 33 studies evaluating 355 markers were included. The diagnostic value of most individual markers was relatively modest, with only 6 markers showing sensitivity >40% at specificity >75% (only 2 (HYAL2 and S100P) were independently validated). Although relatively strong associations (OR<=0.5 or OR>=2) with BC were reported for 14 markers, most of them were not independently validated. Two prospective studies performed epigenome-wide association analysis and identified 276 CpG sites related to BC risk, but no overlap was observed between CpGs reported from these 2 studies. Five studies incorporated individual markers as panels but only 2 of them used a test-validation approach. In conclusion, so far detected methylation markers are insufficient for BC early detection, but markers or marker-combinations may be useful for BC risk stratification. Utilizing high-throughput methods of methylation quantification, future studies should focus on further mining informative methylation markers and derivation of enhanced multi-maker panels with thorough external validation ideally in prospective settings.
000141812 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141812 588__ $$aDataset connected to CrossRef, PubMed,
000141812 7001_ $$0P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aYu, Haixin$$b1$$udkfz
000141812 7001_ $$0P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aCuk, Katarina$$b2$$udkfz
000141812 7001_ $$0P:(DE-He78)d19149dd97b17ce55e70abd2f9e64d3d$$aZhang, Yan$$b3$$udkfz
000141812 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000141812 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-18-0378$$gp. cebp.0378.2018 -$$n3$$p496-505$$tCancer epidemiology, biomarkers & prevention$$v28$$x1538-7755$$y2019
000141812 909CO $$ooai:inrepo02.dkfz.de:141812$$pVDB
000141812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d19149dd97b17ce55e70abd2f9e64d3d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141812 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141812 9141_ $$y2019
000141812 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2017
000141812 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141812 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141812 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141812 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141812 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141812 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141812 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141812 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141812 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141812 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141812 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141812 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000141812 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000141812 980__ $$ajournal
000141812 980__ $$aVDB
000141812 980__ $$aI:(DE-He78)C070-20160331
000141812 980__ $$aI:(DE-He78)L101-20160331
000141812 980__ $$aUNRESTRICTED